The management of PAH has become increasingly complex. With a growing number of PAH-specific therapies, intimate knowledge of the therapeutics and the potential barriers to adherence are integral to providing optimal care for this high-risk patient population. While current PAH-specific therapies largely mediate their effects through pulmonary vasodilation, ongoing research efforts are focused on ways to disrupt the mechanisms leading to pulmonary vascular remodeling. By targeting aberrations identified in the metabolism and proliferative state of pulmonary vascular cells, novel PAH treatment pathways may be just on the horizon.
Keyphrases
- pulmonary hypertension
- pulmonary arterial hypertension
- pulmonary artery
- polycyclic aromatic hydrocarbons
- healthcare
- quality improvement
- induced apoptosis
- case report
- palliative care
- small molecule
- type diabetes
- oxidative stress
- coronary artery
- signaling pathway
- skeletal muscle
- combination therapy
- health insurance
- affordable care act